Compare Equinor ASA (EQNR) vs Medtronic PLC (MDT) Price & Performance

EQNR trades at $41.61, down 3.26% today, with a bearish technical outlook and mixed fundamental performance. The stock shows attractive valuation metrics including P/E of 11.63 and EV/EBITDA of 2.39, but faces declining profit margins from 19.29% in 2022 to 4.76% in 2025. Recent earnings show two beats and one miss, while analyst consensus remains positive with a $87.50 price target representing significant upside potential from current levels.

The investment case balances deep value characteristics against operational headwinds. While valuation appears compelling with strong cash flows and dividend payments, investors face risks from volatile energy markets and margin compression. The 112% upside to consensus target suggests Wall Street sees substantial recovery potential if operational performance improves.

Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.

MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.